iBio’s obesity pipeline advances with long-acting antibody IBIO-610, Q3 2027 trial targets

iBio (IBIO), a San Diego-based biotech company, detailed progress on its obesity pipeline at the Wells Fargo 21st Annual Healthcare Conference in September 2026, highlighting a lead candidate—IBIO-610—a first-in-class long-acting Activin E antibody designed for infrequent dosing. The drug aims to achieve complete blockade of circulating Activin E, a target that competing siRNA approaches can only achieve at ~85% efficacy. Clinical-stage validation began in 2024, with Australia’s planned notification for the first IBIO-610 clinical trial filing by year-end 2024, followed by first patient dosing in early 2025. Interim single ascending dose data is expected six months after dosing begins. IBIO-610’s estimated human half-life of 50 to 100 days supports quarterly or semi-annual administration, addressing a key unmet need in obesity treatment where current therapies require frequent dosing or produce suboptimal weight loss results. The company’s CEO, Martin Brenner, emphasized the market’s evolving complexity, noting obesity’s treatment should not be confined to cosmetic outcomes but rather address its underlying metabolic and systemic health risks. "We’re likely looking at a hypersegmentation of the market," Brenner said, reflecting a shift toward precision medicine approaches. Meanwhile, IBIO-600, a myostatin inhibitor targeting muscle preservation in obesity and sarcopenia, completed single ascending dose enrollment in 2026. Safety and pharmacokinetic data for IBIO-600 are due in Q1 2027. Beyond obesity, iBio’s pipeline includes a bispecific program for pulmonary hypertension with heart failure preserved ejection fraction (PH-HFpEF), with development candidate declaration in June 2024 and a clinical trial filing planned for Q2 or Q3 2027, with first patient dosing targeted for Q3 2027. The company also outlined second-generation programs, including an ALK7 receptor antagonist and an Activin E antibody linked to an incretin molecule. iBio’s antibody discovery platform, developed over eight years and strengthened by acquiring RubrYc Therapeutics assets, screened over 1 billion molecules to identify a single Activin E-neutralizing antibody. The company’s stock, currently trading at $1.30, has seen a 49.8% decline over the past six months and a 53.3% gain over the past year. Analyst price targets range from $4.20 to $7.00, though profitability is not anticipated this year. Phase III obesity trial costs are estimated between $300 million and $800 million. Brenner also highlighted discrepancies between clinical trial outcomes and real-world GLP-1 weight loss, noting that trial results often show 25% to 35% weight loss, whereas real-world data frequently yields only 10%, attributed to dose reductions due to side effects. "Real-world GLP-1 weight loss is often about 10%, well below the 25% to 35% seen in trials," he said, underscoring the need for more durable and patient-friendly solutions. iBio’s Amylin program, which includes four molecules with varying receptor profiles, remains in early development stages, with no finalized candidates for clinical testing.